ME241115P10000
- 0.00
- 0.000.00%
23andMe Newsroom
Citi Maintains 23andMe(ME.US) With Hold Rating, Cuts Target Price to $0.42
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH) and 23andMe Holding (ME)
Hold Rating on 23andMe Amid Clinical and Acquisition Uncertainties
TD Cowen Maintains 23andMe(ME.US) With Buy Rating, Maintains Target Price $2
TD Cowen Reaffirms Their Buy Rating on 23andMe Holding (ME)
23andMe Holding (ME) Buy Rating Justified by Strong Revenue and Strategic Developments
Citigroup Maintains Neutral on 23andMe Holding, Lowers Price Target to $0.47
23andMe Holding Analyst Ratings
Citi: Maintains 23andMe Holding (ME.US) rating, adjusted from neutral to neutral, and adjusted the target price from $0.85 to $0.47.
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and 23andMe Holding (ME)
Analysts Conflicted on These Healthcare Names: Denali Therapeutics (DNLI), BridgeBio Pharma (BBIO) and 23andMe Holding (ME)
Buy Rating for 23andMe on Strategic Restructuring and Potential for Shareholder Value Enhancement
Maintaining a Hold: Balancing 23andMe's Innovative Therapeutic Prospects With Early-Stage Development Risks
Balancing Potential and Risk: Hold Rating on 23andMe Amid Clinical Trial Developments
Citi Keeps Their Hold Rating on 23andMe Holding (ME)
Analysts Conflicted on These Healthcare Names: Sana Biotechnology (SANA), 23andMe Holding (ME) and Invitae (NVTA)
Analysts Conflicted on These Healthcare Names: 23andMe Holding (ME), Tenet Healthcare (THC) and Revvity (RVTY)
Hold Rating on 23andMe Amid Anticipation of Crucial Cancer Therapy Data Presentation
Citigroup Maintains Buy on 23andMe Holding, Lowers Price Target to $1.75
23andMe Holding Analyst Ratings